Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis - A Review by Kenn, K. et al.
E-Mail karger@karger.com
 Thematic Review Series 2013 
 Respiration 2013;86:89–99  
 DOI: 10.1159/000354112 
 Pulmonary Rehabilitation in Patients 
with Idiopathic Pulmonary Fibrosis -
A Review  
 K. Kenn a    R. Gloeckl a    J. Behr b  
 a  Schoen Klinik Berchtesgadener Land, Department of Respiratory Medicine,  Schoenau am Koenigssee , and 
 b  Klinikum der Universität München – Campus Grosshadern, Medizinische Klinik und Poliklinik V, Comprehensive 
Pneumology Center Munich (CPC-M),  Munich , Germany 
the current literature and our own experience, this article will 
try to highlight the importance of PR as an additional, ben-
eficial therapeutic option for patients with IPF. 
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 Introduction 
 Idiopathic pulmonary fibrosis (IPF) is a chronic fibrot-
ic lung disease of unknown cause which is diagnosed pre-
dominantly in elderly males  [1] . The relentlessly progres-
sive course of the disease leads to premature disability and 
death, with a median survival of 2–4 years after diagnosis 
 [1] . A definite diagnosis of IPF requires histologic or radio-
logic (high-resolution computed tomography) evidence of 
an usual interstitial pneumonia (UIP) pattern and the ex-
clusion of known causes of pulmonary fibrosis  [2] . Pir-
fenidone has been shown to reduce the decline of pulmo-
nary function and exercise tolerance in mild to moderate 
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 Abstract 
 Among the various types of interstitial lung diseases, idio-
pathic pulmonary fibrosis (IPF) is the most common disorder 
and has a poor prognosis and a limited response to pharma-
cological treatment. In patients with IPF, functional exercise 
tolerance and quality of life have been shown to be signifi-
cantly decreased. Current IPF guidelines suggest only a weak 
recommendation for pulmonary rehabilitation (PR). Howev-
er, PR is regarded as a reasonable choice for the majority of 
patients with IPF. This review will summarize all of the avail-
able studies that have investigated the effects of PR in pa-
tients with IPF so far. Although only a small number of stud-
ies have been published to date, most studies have found 
significant short-term improvements in functional exercise 
capacity, quality of life, and level of perceived dyspnea. 
Long-term improvements or maintenance strategies of PR in 
IPF patients have not been adequately investigated yet. Up 
to now there is still no sufficient evidence for the recommen-
dation of PR in IPF. However, physical training seems to be 
the major component of all PR programs. The current review 
will discuss potential exercise training regimens for patients 
with IPF and suggest additional useful modalities of a spe-
cific multidisciplinary PR program for IPF patients. Based on 
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IPF and is currently approved in the EU and Japan for the 
pharmacological treatment of IPF. Alternatively, n-acetyl-
cysteine may also reduce the decline of lung function and 
is used off-label to treat IPF. Currently available pharma-
cological therapies are capable to slow disease progression 
and physical deterioration, but improvements are rarely 
observed and cure is illusive [1]. In addition, long-term 
oxygen therapy (LTOT) and supportive therapies for 
cough and comorbidities are offered to the patients  [1] . In 
the face of a severe and fatal disease, lung transplantation 
is a viable treatment option for eligible patients who, how-
ever, are a minority within the IPF population, mainly due 
to progressed age and comorbidities  [1] . Taken together, 
quality of life, exercise capacity, and life expectancy are 
severely impaired in IPF patients, and available treat-
ments – except for lung transplantation – are palliative  [3] . 
Therefore, pulmonary rehabilitation (PR) may be of add-
ed value for stable IPF patients in an attempt to improve 
their ability to cope with daily living.
 The Rationale for PR in IPF Patients 
 IPF is a chronic progressive lung disease leading to in-
creasing levels of dyspnea, dry cough symptoms, and fa-
tigue, inducing reduced exercise capacity and health-re-
lated quality of life (HRQL)  [4] . For patients with chron-
ic obstructive pulmonary disease (COPD), there is a great 
deal of evidence that PR programs have various signifi-
cant and clinically meaningful benefits such as improved 
exercise capacity, HRQL, and symptoms of dyspnea. 
COPD patients are especially limited by impaired respira-
tory mechanics, hyperinflation, and musculoskeletal dys-
function. The benefits of PR in these clinical outcome pa-
rameters have been widely investigated and are well prov-
en in patients with COPD  [5–7] . In patients with IPF an 
impaired gas exchange seems to be the major cause of 
exercise intolerance  [1, 8, 9] .
 After dyspnea, the most important symptoms patients 
of both chronic lung diseases also suffer from are extra-
pulmonary manifestations like reduced exercise tolerance 
and HRQL, fatigue, and/or anxiety and depression  [9–13] .
 Even if IPF and COPD are entities with very different 
pathophysiological mechanisms, in many respects they 
lead to some similar limitations for patients’ everyday life 
and thus may reflect a similar burden of disease. With re-
gard to these similarities, it seems plausible that PR may 
also be beneficial in patients with IPF.
 PR as a comprehensive, multidisciplinary program 
uses a combination of exercise training, education, and 
behavior modification techniques to optimize functional 
capacity, improve self-management, reduce symptoms, 
and increase participation in activities of daily living 
(ADL) in patients with chronic lung disease  [6] . As IPF is 
a disease with a limited response to conventional phar-
macological treatment  [14] , PR as a nonpharmacological 
approach may be promising also in these patients. The 
American Thoracic Society (ATS)/European Respiratory 
Society (ERS) statement on PR from 2006 expressed that 
‘… there are no formal evidence-based guidelines regard-
ing the exercise prescription or response to exercise train-
ing for patients with respiratory disorders other than 
COPD. Therefore, recommendations for PR concerning 
these diseases can only rely on expert opinion based on 
knowledge of the underlying pathophysiological and 
clinical experience’  [6] . The ATS/ERS statement is cur-
rently being updated and will be published in 2013. Most 
likely the level of evidence of PR in patients with IPF can 
be expected to be strengthened. However, an official 
statement  [1] of the ATS, the ERS, the Japanese Respira-
tory Society (JRS), and the Latin American Thoracic As-
sociation (ALAT) concluded that ‘… the recommenda-
tion for PR in patients with IPF is weak. Nevertheless, it 
is stated that … PR should be used in the majority of pa-
tients with IPF, but not using PR may also be a reasonable 
choice in a minority. Further research is very likely to 
have an important impact on the boards’ confidence in 
the estimate of effect and is likely to change the estimate’ 
 [1] .
 Since IPF is known as a heterogeneous disorder in 
terms of disease progression, response to therapy, and 
prognosis  [1] , the optimal timing of PR in the disease tra-
jectory is still unknown and requires further elaboration 
 [15] . It is still unclear whether the decline in functional 
capacity could be decelerated or delayed if patients are 
referred to PR in any phase of the disease. So far there is 
no data showing the potential influence of PR on the clin-
ical course or even on the prognosis of the disease. This 
review will highlight the current knowledge concerning 
the various components of a comprehensive PR process.
 Exercise Training Regimens in IPF 
 The authors of the current review identified via a lit-
erature search 7 studies that investigated PR in patients 
with IPF ( table 1 ). PR duration varied from 6 to 12 weeks 
and was applied mostly as outpatient PR. In only a few 
studies was PR offered in a home-based fashion. Most 
studies included only a small sample size (n = 17, 17, 21, 
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25, 30, 34, 45, and 65) and varied in scientific quality 
(from prospective, observational studies without a con-
trol group to randomized, controlled trials). In all of these 
studies exercise training was the major component. All 
trials provided a combination of endurance and strength 
training modalities as is also recommended in patients 
with COPD  [16, 60] . Endurance training was performed 
on a stationary cycle ergometer or as a walking program 
on a treadmill or on the ground. If specified, cycling train-
ing was applied for sessions of 5–30 min. Training inten-
sity was adjusted either to 50%  [17, 18] or to 80%  [19] of 
the peak work rate (PWR), to the target heart rate at the 
ventilatory threshold  [20] , or to 60% of the predicted 
maximum heart rate for that age  [21] . All cycle training 
protocols were based on continuous endurance training 
programs. None of the studies provided information on 
the feasibility of those endurance training protocols. 
When available, walking-based training programs were 
applied at 80% of the 6-min walk test (6MWT) speed  [19, 
22] or at 60% of the predicted maximum heart rate for 
that age  [21] . In the study of Kozu et al.  [18] , a ground 
walking-based endurance training program for severely 
disabled IPF patients [n = 15, forced vital capacity (FVC) 
= 51% predicted, MRC scale 5] was conducted using an 
interval training approach (1 min at 100% of the 6MWT 
speed in turns with 1 min of 50%). No information was 
provided on the total exercise duration or on how the pa-
tients controlled their walking speed on the ground.
 Strength training regimens within these studies in-
cluded even more heterogeneous approaches. Most stud-
ies  [19–22] did not provide detailed information on how 
resistance training was applied. It was only mentioned 
that ‘functional strength training was performed’. Other 
studies  [17, 18, 23] described that 1–3 sets of 10 repeti-
tions of strength training for the upper and lower limbs 
were used. None of the studies provided any information 
about the level of intensity at which resistance training 
was performed.
 The analyzed studies showed, in general, large varia-
tions in the described exercise modalities, duration, and 
intensity. Therefore, it is not possible to derive any con-
sistent training protocol for an ideal exercise training 
program from the included studies. However, even differ-
ent training regimens seem beneficial for patients with 
IPF, if applied. 
 No exercise-related adverse effects were mentioned in 
any study. This finding supports the conclusion of a Co-
chrane Review which stated that physical training is safe 
for subjects suffering from interstitial lung disease (ILD) 
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 Education and Breathing Retraining 
 An educational part was also a component of PR pro-
grams in several studies. In most educational programs 
information on breathing techniques, coping strategies, 
pacing during ADL, and energy conservation were pro-
vided  [17–19, 21] . None of these trials offered detailed 
information on the specific content of these education 
sessions. Further studies should evaluate the particular 
needs of IPF patients and develop IPF-specific education-
al programs.
 One of the most highlighted parts of the patient edu-
cational programs was breathing retraining. Since pursed-
lip breathing (PLB) is one of the most favored breathing 
techniques in patients with COPD  [25] , it remains un-
known whether patients with IPF would also benefit from 
PLB. Although most studies that provided breathing re-
training to IPF patients also used the PLB technique, the 
respiratory pathophysiologies of COPD and IPF are very 
different. Since patients with IPF do not suffer from ob-
structed airways, it is not likely that positive expiratory 
pressure breathing may be helpful primarily. Use of an 
intense PLB technique could increase the work of breath-
ing in patients with restrictive lung diseases. The respira-
tory pathophysiology in IPF requires an increased breath-
ing frequency, especially during physical activity. How-
ever, some patients tend to develop an unnecessary degree 
of hyperventilation. In order to regain breathing control, 
a slight PLB technique could be helpful to adjust the 
breathing frequency to an appropriate level even in IPF 
patients. 
 Generally, in IPF the emphasis in breathing retraining 
should be on teaching those techniques for breathing 
control and diaphragmatic effort to prevent tachypnea 
and anxiety and to improve gas exchange  [26] . Since 
many IPF patients develop rigid rib cage structures, tho-
racic expansion exercises or stretching of the thoracic 
muscles may also be beneficial in patients with restrictive 
lung diseases. 
 Exercise Capacity 
 Only one of the studies  [19] was performed as a ran-
domized controlled trial investigating PR versus a con-
trol group in patients with IPF. Twenty-eight patients 
(FVC = 69% predicted) were randomly assigned either to 
a 10-week outpatient PR program (n = 13) mainly con-
sisting of exercise training or to a control group. The con-
trol group (n = 15) did not receive any physical interven-
tion. Measurements lung function, arterial blood gases, 
or dyspnea intensity revealed no significant effects of PR. 
Nevertheless, the 6-min walk distance (6MWD) im-
proved significantly only in the PR group, whereas it re-
mained unchanged in the control group (mean difference 
between groups in change from baseline 46.3 m; p < 0.01; 
95% CI 8.3–84.4 m).
 All other studies except for one  [20] included in this 
review also found significant short-term improvements 
in exercise capacity in patients with IPF following PR. Ex-
ercise capacity was mainly determined by the 6MWD. 
Only half of the studies  [18, 19, 21, 23] achieved an in-
crease in walk distance above the expected minimal im-
portant difference (MID) of about 28 m for IPF patients 
 [27] ( fig.  1 ). There were no obvious different variables 
with regard to the study populations (disease severity 
etc.) or to the different PR programs that might have ex-
plained these heterogeneous results.
 In a small trial  [20] (n = 13 IPF patients, FVC = 67% 
predicted) no changes in 6MWD (383 ± 115 vs. 375 ±
101 m; n.s.) following a mostly unsupervised 8-week home-
based PR program were observed. Nevertheless, a signifi-
cant decrease in maximum heart rate during the 6MWD 
was reported (120 ± 19 vs. 101 ± 12 bpm; p < 0.01). Surpris-
ingly, patients showed an endurance time which was twice 
as high after PR (7.4 ± 9.1 vs. 14.1 ± 12.0 min; p < 0.01) on 
a cycle ergometer while breathing room air. This might be 
due to the fact that this PR program was mainly focused on 
a cycling-based exercise program. However, the small sam-
ple size of this study has to be considered.
 Kozu et al.  [17] also evaluated changes in quadriceps 
strength in 36 IPF patients (FVC = 69% predicted) follow-
ing an 8-week outpatient PR program and reported an 
increase of 10% in the maximal isometric knee extension 
maneuver. This is substantially less than what can be ex-
pected in patients with COPD. On average, COPD pa-
tients have been shown to improve their quadriceps 
strength after PR by up to 25%  [28] .
 Also the disease severity of IPF may play a role in im-
proving exercise capacity after PR, although there are in-
consistent findings. A Japanese study  [18] enrolled 65 IPF 
patients (FVC = 65% predicted) in an 8-week PR pro-
gram. Subjects with Medical Research Council (MRC; 
grades 1–5) grades 2, 3, and 4  [29] underwent a super-
vised outpatient program, whereas subjects with MRC 
grade 5 participated in an unsupervised, home-based 
program including a visit from a home care provider ev-
ery 2 weeks. In this study only patients with MRC grades 
2 and 3 improved their 6MWD significantly. In contrast, 
patients with MRC grade 4 showed only small improve-
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ments, and those with grade 5 showed no improvements. 
In contrast to these findings, a recently published study 
by Huppmann et al.  [30] investigated a specialized, com-
prehensive, 4-week inpatient PR program in 402 Ger-
man patients with ILD (including 202 IPF patients, mean 
VC = 53% predicted). The improvement in 6MWD after 
PR was 45 ± 55 m (range –130 to 236 m), approximately 
15% of the baseline value (p < 0.001). Of all of the vari-
ables tested (age, gender, BMI, smoking history, use of 
LTOT, baseline FVC, baseline 6MWD, and baseline dys-
pnea), only the baseline 6MWD was a significant predic-
tor of change in 6MWD. The mean improvement in 
6MWD was higher in patients with a short baseline 
6MWD ( fig. 2 ). A subgroup analysis showed significant 
improvements in ILD patients independently of their un-
derlying form of ILD ( fig. 3 ).
 What might be possible reasons for such contrasting 
results between the publications of Kozu et al.  [18] and 
Huppmann et al.  [30] ? Firstly, in the study by Kozu et al. 
 [18] the most disabled patients (MRC grade 5) with a 
mean vital capacity (VC) of 51% predicted underwent 
home-based and mostly unsupervised exercise training, 
which might not be the ideal approach for such severely 
impaired patients. Secondly, the MRC dyspnea scale may 
not be an appropriate tool to categorize and predict the 
changes in 6MWD in IPF patients. As the study by 
Huppmann et al.  [30] investigated a very large and equal-
ly disabled population (n = 202 IPF patients, mean VC 
53% predicted), the authors assumed that an intensive su-
pervised PR might be more appropriate, especially in IPF 
patients with a severely impaired physical condition. This 
association was also confirmed by a retrospective study 
 [31] that examined the effects of PR in 99 patients with 
ILD (mean FVC = 62% predicted, n = 50 with IPF). These 
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 Fig. 1. Changes in 6MWD in patients with 
IPF following PR. The dashed line repre-
sents the MID of 28 m in 6MWD in pa-
tients with IPF  [27] . 
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 Fig. 2. The bars show the mean change in 6MWD during PR be-
tween admission and discharge depending on the baseline 6MWD 
in 202 patients with IPF. Data are provided by courtesy of 
Huppmann et al.  [30] . 
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authors also reported a negative correlation between low-
er baseline 6MWD and a greater increase following PR.
 However, since exercise capacity has been recognized 
as a crucially important prognostic factor in IPF  [32, 33] , 
PR should mainly focus on improvement of the physical 
condition in those patients.
 Quality of Life 
 Almost all of the studies in this review used different 
assessment measures to evaluate HRQL. Only two studies 
 [21, 23] used the short-form 36-item (SF-36) question-
naire (scale 0–100), a disease-unspecific health survey 
tool. After a 12-week home-based PR program (n = 15 
IPF patients, FVC = 72% predicted), Ozalevli et al.  [23] 
found significant improvements after PR in 3 out of 8 SF-
36 domains, i.e. general health (57 vs. 74 points, p < 0.05), 
physical role (25 vs. 68 points, p < 0.01), and emotional 
role (29 vs. 65 points, p < 0.05). Since the MID for the SF-
36 questionnaire in IPF is assumed at a range of 2–4 
points  [34] , these improvements would represent a tre-
mendous increase in these domains. However, from our 
perspective, this degree of improvement in SF-36 do-
mains raises doubts. In contrast, Swigris et al.  [21] found 
no significant improvement in any SF-36 domain after a 
6-week outpatient PR program in 21 IPF patients (FVC = 
73% predicted), but they did find a possibly clinically rel-
evant increase of 3.0 ± 2.1 in the physical component 
summary score. However, at least fatigue, a very bother-
some symptom, was significantly reduced in this study 
(fatigue severity scale 4.2 vs. 2.7; p = 0.01). 
 Nishiyama et al.  [18] used the Saint George respiratory 
questionnaire (SGRQ) to evaluate HRQL during a 10-
week outpatient PR in 30 IPF patients (FVC = 69% pre-
dicted). Only the change in total SGRQ score reached a 
significant difference in favor of the PR group versus the 
control group not receiving PR (6.1 points, between-
group difference, p < 0.05). In patients with IPF, an im-
provement in SGRQ score of 5–8 points is estimated to 
be the MID  [34] .
 Although several studies reported inconsistent results 
on HRQL, there is a strong indication that PR reveals 
HRQL benefits to a clinically relevant extent in IPF pa-
tients.
 Dyspnea 
 To evaluate dyspnea as one of the most relevant dis-
ease-specific symptoms, the dyspnea domain of the 
chronic respiratory questionnaire (CRQ) with an as-
sumed MID threshold of 2.5 points  [35] was used in the 
study by Holland et al.  [22] . After an 8-week outpatient 
PR program (n = 25, FVC = 76% predicted), an improve-
ment of 2.7 ± 5.6 points (p > 0.05) could be reached in the 
CRQ dyspnea domain. At program completion, 59% of 
the IPF patients had achieved improvements in dyspnea 
exceeding the MID. This is less than the rate detected in 
a population of 19 patients with non-IPF ILDs (67%) in 
this trial.
 Two other studies  [17, 18] investigated the effect of PR 
on dyspnea using Mahler’s transition dyspnea index 
(TDI)  [36] . This interviewer-administered questionnaire 
provides a multidimensional measurement of dyspnea 
that evokes dyspnea in ADL. With an overall increase of 
0.8 ± 1.7 points after an 8-week outpatient PR, these stud-
ies failed to show a significant or clinically relevant im-
provement in dyspnea, except for IPF patients catego-
rized as MRC grade 2. These patients were able to im-
prove their TDI by 1.6 points (95% CI 1.0–2.3), which is 
closely above the discussed MID of 1.5 points in patients 
with ILD  [37] . Rammaert et al.  [20] assessed breathless-
MID
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 Fig. 3. The bars show the effects of PR on the 6MWD in different 
types of ILD. Data are provided courtesy of Huppmann et al.  [30] . 
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ness using a visual analog scale (0–10 points) and found 
a significant reduction (5.8 ± 1.8 vs. 5.1 ± 2.4; p < 0.025) 
in dyspnea in IPF patients following an 8-week home-
based PR.
 PR in IPF versus Non-IPF Patients 
 The above mentioned recently published study  [30] 
evaluated 402 patients with ILD (including 202 IPF pa-
tients, mean VC = 53% predicted) following a 4-week in-
patient PR program. The authors found significant and 
clinically relevant improvements in functional exercise 
capacity (increase in 6MWD 46 ± 3 m) as well as HRQL 
(SF-36 physical component score +6 ± 1 points; SF-36 
mental component score +10 ± 1 points; both p < 0.001). 
These benefits were independent of the underlying dis-
ease (IPF, cryptogenic organizing pneumonia, hypersen-
sitivity pneumonitis, sarcoidosis, and others) ( fig. 3 ). Pa-
tients with signs of pulmonary hypertension (PH) showed 
a decreased baseline 6MWD (277 ± 12 vs. 322 ± 8 m) and 
improved their 6MWD significantly less than did patients 
without PH (36 ± 6 vs. 48 ± 3 m, p = 0.045). However, the 
increase in 6MWD in ILD patients with PH was still sig-
nificant and clinically meaningful  [27] .
 In contrast, Holland et al.  [22] found greater and more 
sustained benefits from PR when IPF severity was still 
mild, whereas those with other types of ILD achieved ben-
efits regardless of disease severity. In IPF, greater im-
provements in 6MWD following PR were associated with 
a higher FVC (r = 0.49, p = 0.01), less exercise-induced 
hypoxemia (r s = 0.43, p = 0.04), and lower right ventricu-
lar systolic pressure (r = –0.47, p = 0.1). Moreover, pa-
tients with IPF also tended to improve their functional 
exercise capacity less than those with other types of ILDs 
(6MWD 21 ± 58 vs. 43 ± 56 m, p = 0.21). Improvements 
in 6MWD that exceeded the MID occurred in 40% of pa-
tients with IPF compared to 52% of those with other 
forms of ILD (p = 0.41). A comparable cluster could be 
found concerning improvements in patients’ dyspnea 
rating. The CRQ dyspnea domain improved slightly less 
in IPF patients compared to other types of ILD (2.7 ± 5.6 
vs. 4.6 ± 5.2 points, p = 0.25).
 Since ILD is a heterogeneous group of disease, these 
authors hypothesized that patients with IPF would gener-
ally demonstrate greater abnormalities of exercise-in-
duced hypoxemia  [38, 39] and tend to improve less fol-
lowing PR  [22] . The latter would not be in accordance 
with the findings of Huppmann et al.  [30] .
 Moreover, when comparing the effects of an identical 
PR program for patients with COPD or IPF, COPD pa-
tients showed greater improvements in all outcome pa-
rameters compared to IPF patients (6MWD 53 vs. 16 m, 
quadriceps force 5.4 vs. 2.0 kg, TDI score 1.8 vs. 0.8 points; 
all between-group differences with p < 0.05)  [17] . So far 
the underlying reasons for the different responses to PR 
between the two diseases remain unclear. 
 Maintenance of PR Benefits in IPF 
 In patients with COPD it is known that the benefits of 
PR can be maintained for up to 12–18 months  [6] . To date 
there is no reliable evidence of long-term effects of PR in 
patients with IPF. In a single small study  [40] including 
34 patients (FVC = 76% predicted), no effects of physical 
training on exercise capacity, HRQL, or survival could be 
preserved over a period of 6 months after PR. Only a small 
subgroup with severe disease still had significantly im-
proved HRQL compared to controls at that time. It also 
seems to be much more unlikely for patients with IPF to 
preserve benefits of PR compared to other forms of ILD. 
Six months after PR, only 35% of patients with IPF had 
maintained gains in 6MWD that exceeded the MID, com-
pared to 41% of patients with other types of ILD. Also, 
improvements in dyspnea above the MID were observed 
in non-IPF patients more often compared to IPF patients 
(56 vs. 24%; p < 0.05) at 6 months after PR. However, in 
another small study Naji et al.  [41] (n = 15 ILD patients, 
no notification on IPF) reported improvements in exer-
cise capacity that were still maintained 1 year after PR. 
The authors even found a sustained and significant re-
duction in hospital admission days noted 1 year after the 
intervention.
 In a Japanese study  [17] , the limitations of ADL were 
assessed using a standard scoring system  [42] . This ADL 
score evaluates 6 basic daily activities (feeding, transfer, 
dressing, bathing, shopping, and transportation). The 
ADL score improved significantly after an 8-week PR 
program and this was the only outcome parameter that 
could be preserved over a 6-month follow-up period (3.7 
± 1.2 vs. 4.8 ± 1.1 vs. 4.3 ± 1.2; all p < 0.01). At follow-up 
all other parameters (6MWD, quadriceps force, SF-36, 
MRC grade) declined to baseline values before PR. The 
finding that the ADL score was preserved at follow-up 
was explained by the patient education component that 
aimed to improve the ability of subjects to perform ADLs.
 The duration of the PR program may also play a cer-
tain role. One study  [43] investigated 10 patients with 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:3
1:
31
 P
M
 Pulmonary Rehabilitation in IPF Respiration 2013;86:89–99
DOI: 10.1159/000354112
97
ILDs (FVC = 47% predicted) and observed highly rele-
vant benefits in clinical outcome parameters after 12 
weeks of PR, with an even greater gain when the program 
was extended to 24 weeks (6MWD baseline 321 ± 155 m 
vs. 400 ± 184 m vs. 428 ± 211 m; each p < 0.05). Neverthe-
less, for many health care systems it might be difficult to 
establish such long-lasting PR programs. Indeed, a con-
ceivable solution could be to instruct and motivate pa-
tients to maintain home-based follow-up training modal-
ities in order to sustain PR benefits  [44] .
 Unmet Needs for an IPF-Specific PR Approach 
 The question of which aims should be addressed and 
which components ideally should be included in an IPF-
specific PR program remains unanswered. It is not yet 
known which modifications of PR programs for IPF pa-
tients may be useful or necessary in comparison to PR 
programs for patients with COPD. However, one study 
 [17] could show that a PR program based on guidelines 
for subjects with COPD had a lower efficacy when applied 
to individuals with advanced IPF. These results suggest 
either that a disease-specific modification of PR programs 
might be necessary in IPF or that the response to the var-
ious components of PR may be more limited due to the 
different underlying pathophysiologies of ILDs, especial-
ly IPF.
 Nevertheless, with regard to the above described stud-
ies, it seems to be likely that individually tailored exercise 
training (a combination of aerobic endurance and 
strength training) may also be an important component 
in PR in patients with IPF. Exercise training was the only 
modality applied in all studies that investigated PR in IPF. 
To date, it is unclear whether IPF patients would require 
different training strategies than COPD patients. Espe-
cially for more severely disabled IPF patients, endurance 
training may be more feasible when applied as an interval 
training mode with short bouts of high-intensity cycling 
alternating with longer periods of rest as shown in ad-
vanced COPD  [45] . One can speculate that this might be 
even more important since IPF patients seem to perceive 
higher degrees of dyspnea on exertion  [46] and thus a 
more pronounced limitation in endurance capacity com-
pared to patients with COPD. Furthermore, disease-spe-
cific education including coping skills and self-manage-
ment plans for situations of severe dyspnea in order to 
prevent or to reduce panic attacks, stress, anxiety, and/or 
depression could be a useful component in an IPF-specif-
ic PR program. Additionally, disease-specific breathing 
retraining sessions (e.g. respiratory control or reducing 
tachypnea) as well as teaching energy conservation strat-
egies may also be helpful adjuncts for the patients’ daily 
life. As we have learned from COPD patients, the issue of 
psychiatric comorbidities such as anxiety, panic, and/or 
depression  [47] as well as end-of-life communication  [48] 
represents a relevant part of the burden even in early 
phases of the disease. It is most likely that in IPF patients 
these issues should be considered and addressed in the 
general disease management. PR may be an appropriate 
‘window of opportunity’ to deal with these problems. 
Studies in this area are lacking.
 The role of oxygen supplementation (LTOT) in pa-
tients with hypoxemia during exertion and/or at rest (not 
addressed in the discussed trials but probably of high clin-
ical relevance) has to be discussed and evaluated in the 
future. Currently the IPF-specific guidelines include a 
strong recommendation, albeit with very low-quality ev-
idence, for the use of LTOT  [1] . In our opinion, sufficient 
compensation in oxygen deficiencies may be an impor-
tant key for increasing the ability of IPF patients to per-
form and to sustain any kind of physical activity. How-
ever, potential negative effects of oxygen, although never 
reported in IPF patients, have to be considered and ruled 
out. Consequently there is definitely an unmet need for 
further studies in this area.
 New training modalities besides conventional exercise 
methods, such as neuromuscular electrical muscle stimu-
lation  [49, 50] , inspiratory muscle training  [51, 52] , 
whole-body vibration training  [53] , or noninvasive ven-
tilation  [54, 55] , have been shown to be beneficial in pa-
tients with advanced COPD. It could be hypothesized 
that these therapeutic interventions may also be useful in 
IPF. The same may be true for alternative exercise and 
relaxation techniques like tai chi or yoga which have re-
cently been shown to improve HRQL and even lung func-
tion  [56–58] in COPD. Still, there remain many unan-
swered questions for an IPF-specific PR program: what is 
the optimal duration and intensity for PR? What is the 
ideal timing for PR in disease progression? What strate-
gies can be established to preserve PR benefits over time? 
 Conclusion 
 Although positive short-term effects of PR in patients 
with IPF have been reported in several studies, its role in 
the context of an available therapeutic option has yet to 
be established. Future studies have to evaluate if there is 
a need for a standardized IPF-specific PR program also 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:3
1:
31
 P
M
 Kenn  /Gloeckl  /Behr  
 
Respiration 2013;86:89–99
DOI: 10.1159/000354112
98
 References 
 1 Raghu G, Collard HR, Egan JJ, Martinez FJ, 
Behr J, Brown KK, et al: An official ATS/ERS/
JRS/ALAT statement: idiopathic pulmonary 
fibrosis – evidence-based guidelines for diag-
nosis and management. Am J Respir Crit Care 
Med 2011; 183: 788–824. 
 2 Poletti V, Ravaglia C, Buccioli M, Tantalocco 
P, Piciucchi S, Dubini A, Carloni A, Chilosi 
M, Tomassetti S: Idiopathic pulmonary fibro-
sis: diagnosis and prognostic evaluation. Res-
piration 2013; 86: 5–12. 
 3 Cottin V, Camus P: Practical issues and chal-
lenges in idiopathic pulmonary fibrosis. Res-
piration 2013; 86: 1–4. 
 4 Selman M, Thannickal VJ, Pardo A, Zisman 
DA, Martinez FJ, Lynch JP 3rd: Idiopathic 
pulmonary fibrosis: pathogenesis and thera-
peutic approaches. Drugs 2004; 64: 405–430. 
 5 Lacasse Y, Martin S, Lasserson TJ, Goldstein 
RS: Meta-analysis of respiratory rehabilita-
tion in chronic obstructive pulmonary dis-
ease: a Cochrane systematic review. Eura 
Medicophys 2007; 43: 475–485. 
 6 Nici L, ZuWallack R, Wouters E, Donner CF: 
The ATS/ERS statement on pulmonary reha-
bilitation. Eur Respir J 2006; 28: 461–462. 
 7 Harrison SL, Greening NJ, Williams JE, Mor-
gan MD, Steiner MC, Singh SJ: Have we un-
derestimated the efficacy of pulmonary reha-
bilitation in improving mood? Respir Med 
2012; 106: 838–844. 
 8 Katzenstein AL, Myers JL: Idiopathic pulmo-
nary fibrosis: clinical relevance of pathologic 
classification. Am J Respir Crit Care Med 
1998; 157: 1301–1315. 
 9 GOLD: Global strategy of the diagnosis, man-
agement, and prevention of chronic obstruc-
tive pulmonary disease. 2013. http://www.
goldcopd.org (accessed May 3, 2013). 
 10 Ryerson CJ, Arean PA, Berkeley J, Carrieri-
Kohlman VL, Pantilat SZ, Landefeld CS, et al: 
Depression is a common and chronic comor-
bidity in patients with interstitial lung disease. 
Respirology 2012; 17: 525–532. 
 11 Widimsky J, Riedel M, Stanek V: Central hae-
modynamics during exercise in patients with 
restrictive pulmonary disease. Bull Eur Phys-
iopathol Respir 1977; 13: 369–379. 
 12 Chang JA, Curtis JR, Patrick DL, Raghu G: 
Assessment of health-related quality of life in 
patients with interstitial lung disease. Chest 
1999; 116: 1175–1182. 
 13 Swigris JJ, Kuschner WG, Jacobs SS, Wilson 
SR, Gould MK: Health-related quality of life 
in patients with idiopathic pulmonary fibro-
sis: a systematic review. Thorax 2005; 60: 588–
594. 
 14 Rafii R, Juarez MM, Albertson TE, Chan AL: 
A review of current and novel therapies for 
idiopathic pulmonary fibrosis. J Thorac Dis 
2013; 5: 48–73. 
 15 Dowman L, McDonald CF, Hill C, Lee A, 
Barker K, Boote C, et al: The benefits of exer-
cise training in interstitial lung disease: proto-
col for a multicentre randomised controlled 
trial. BMC Pulm Med 2013; 13: 8. 
 16 Puhan MA, Schunemann HJ, Frey M, Schar-
platz M, Bachmann LM: How should COPD 
patients exercise during respiratory rehabili-
tation? Comparison of exercise modalities 
and intensities to treat skeletal muscle dys-
function. Thorax 2005; 60: 367–375. 
 17 Kozu R, Senjyu H, Jenkins SC, Mukae H, 
Sakamoto N, Kohno S: Differences in re-
sponse to pulmonary rehabilitation in idio-
pathic pulmonary fibrosis and chronic ob-
structive pulmonary disease. Respiration 
2011; 81: 196–205. 
 18 Kozu R, Jenkins S, Senjyu H: Effect of disabil-
ity level on response to pulmonary rehabilita-
tion in patients with idiopathic pulmonary 
fibrosis. Respirology 2011; 16: 1196–1202. 
 19 Nishiyama O, Kondoh Y, Kimura T, Kato K, 
Kataoka K, Ogawa T, et al: Effects of pulmonary 
rehabilitation in patients with idiopathic pul-
monary fibrosis. Respirology 2008; 13: 394–399. 
 20 Rammaert B, Leroy S, Cavestri B, Wallaert B, 
Grosbois JM: Home-based pulmonary reha-
bilitation in idiopathic pulmonary fibrosis. 
Rev Mal Respir 2011; 28:e52–e57. 
 21 Swigris JJ, Fairclough DL, Morrison M, Make 
B, Kozora E, Brown KK, et al: Benefits of pul-
monary rehabilitation in idiopathic pulmo-
nary fibrosis. Respir Care 2011; 56: 783–789. 
 22 Holland AE, Hill CJ, Glaspole I, Goh N, Mc-
Donald CF: Predictors of benefit following 
pulmonary rehabilitation for interstitial lung 
disease. Respir Med 2012; 106: 429–435. 
 23 Ozalevli S, Karaali HK, Ilgin D, Ucan ES: Ef-
fect of home-based pulmonary rehabilitation 
in patients with idiopathic pulmonary fibro-
sis. Multidiscip Respir Med 2010; 5: 31–37. 
 24 Holland A, Hill C: Physical training for inter-
stitial lung disease. Cochrane Database Syst 
Rev 2008, p CD006322. 
 25 Holland AE, Hill CJ, Jones AY, McDonald 
CF: Breathing exercises for chronic obstruc-
tive pulmonary disease. Cochrane Database 
Syst Rev 2012; 10:CD008250. 
 26 Swigris JJ, Brown KK, Make BJ, Wamboldt 
FS: Pulmonary rehabilitation in idiopathic 
pulmonary fibrosis: a call for continued inves-
tigation. Respir Med 2008; 102: 1675–1680. 
 27 Swigris JJ, Wamboldt FS, Behr J, du Bois RM, 
King TE, Raghu G, et al: The 6 minute walk in 
idiopathic pulmonary fibrosis: longitudinal 
changes and minimum important difference. 
Thorax 2010; 65: 173–177. 
 28 O’Shea SD, Taylor NF, Paratz JD: Progressive 
resistance exercise improves muscle strength 
and may improve elements of performance of 
daily activities for people with COPD: a sys-
tematic review. Chest 2009; 136: 1269–1283. 
addressing psychiatric comorbidities and including end-
of-life communication. Moreover the optimal timing 
and duration of PR have to be detected. According to the 
still low level of evidence for PR, only a minority of pa-
tients with IPF have been referred to PR. Currently, many 
physicians as well as patients themselves still believe that 
exercise training may not be feasible or may even be 
harmful  [59] . Data from this review show clinically im-
portant effects (at least on a short-term basis) for patients 
across the spectrum of different types of ILD. Thus PR 
may evolve into a meaningful additional option in the 
treatment of patients with IPF in the future. As has been 
demonstrated in COPD, the inclusion of exercise train-
ing performed most likely as a combination of endurance 
and resistance training seems to be the most important 
component and might become highly recommendable. 
Additionally, a disease-specific educational program as 
well as special breathing retraining sessions may also be 
useful adjuncts to augment patients’ disease manage-
ment.
 Based on our current knowledge, admission criteria 
for PR programs should also include the group of IPF pa-
tients and facilitate their early and repetitive participa-
tion. Future research is needed and should focus on the 
proof of concept that PR is effective in IPF patients and 
that the benefits can be preserved over time, thus posi-
tively impacting the clinical course of the disease. In the 
long run it must be evaluated whether there is a need for 
IPF-specific PR programs as an important part of this 
nonpharmaceutical therapeutic approach.
 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:3
1:
31
 P
M
 Pulmonary Rehabilitation in IPF Respiration 2013;86:89–99
DOI: 10.1159/000354112
99
 29 Fletcher CM, Elmes PC, Fairbairn AS, Wood 
CH: The significance of respiratory symp-
toms and the diagnosis of chronic bronchitis 
in a working population. Br Med J 1959; 2: 
 257–266. 
 30 Huppmann P, Sczepanski B, Boensch M, 
Winterkamp S, Schönheit-Kenn U, Neurohr 
C, Behr J, Kenn K: Effects of in-patient pulmo-
nary rehabilitation in patients with interstitial 
lung disease. Eur Respir J 2012;42:444–445. 
 31 Ferreira A, Garvey C, Connors GL, Hilling L, 
Rigler J, Farrell S, et al: Pulmonary rehabilita-
tion in interstitial lung disease: benefits and 
predictors of response. Chest 2009; 135: 442–
447. 
 32 Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, 
Sonett JR, Kawut SM: Six-minute-walk dis-
tance predicts waiting list survival in idio-
pathic pulmonary fibrosis. Am J Respir Crit 
Care Med 2006; 174: 659–664. 
 33 Swigris JJ, Swick J, Wamboldt FS, Sprunger D, 
du Bois R, Fischer A, et al: Heart rate recovery 
after 6-min walk test predicts survival in pa-
tients with idiopathic pulmonary fibrosis. 
Chest 2009; 136: 841–848. 
 34 Swigris JJ, Brown KK, Behr J, du Bois RM, 
King TE, Raghu G, et al: The SF-36 and 
SGRQ: validity and first look at minimum im-
portant differences in IPF. Respir Med 2010; 
 104: 296–304. 
 35 Jaeschke R, Singer J, Guyatt GH: Measure-
ment of health status: ascertaining the mini-
mal clinically important difference. Control 
Clin Trials 1989; 10: 407–415. 
 36 Mahler DA, Weinberg DH, Wells CK, Fein-
stein AR: The measurement of dyspnea: con-
tents, interobserver agreement, and physio-
logic correlates of two new clinical indexes. 
Chest 1984; 85: 751–758. 
 37 Khanna D, Tseng CH, Furst DE, Clements PJ, 
Elashoff R, Roth M, et al: Minimally impor-
tant differences in the Mahler’s transition 
dyspnoea index in a large randomized con-
trolled trial – results from the Scleroderma 
Lung Study. Rheumatology (Oxford) 2009; 
 48: 1537–1540. 
 38 Agusti AG, Roca J, Rodriguez-Roisin R, Xau-
bet A, Agusti-Vidal A: Different patterns of 
gas exchange response to exercise in asbesto-
sis and idiopathic pulmonary fibrosis. Eur 
Respir J 1988; 1: 510–516. 
 39 Wells AU, Hansell DM, Rubens MB, Cailes 
JB, Black CM, du Bois RM: Functional im-
pairment in lone cryptogenic fibrosing alveo-
litis and fibrosing alveolitis associated with 
systemic sclerosis: a comparison. Am J Respir 
Crit Care Med 1997; 155: 1657–1664. 
 40 Holland AE, Hill CJ, Conron M, Munro P, 
McDonald CF: Short term improvement in 
exercise capacity and symptoms following ex-
ercise training in interstitial lung disease. 
Thorax 2008; 63: 549–554. 
 41 Naji NA, Connor MC, Donnelly SC, McDon-
nell TJ: Effectiveness of pulmonary rehabilita-
tion in restrictive lung disease. J Cardiopulm 
Rehabil 2006; 26: 237–243. 
 42 Spector WD, Katz S, Murphy JB, Fulton JP: 
The hierarchical relationship between activi-
ties of daily living and instrumental activities 
of daily living. J Chronic Dis 1987; 40: 481–489. 
 43 Salhi B, Troosters T, Behaegel M, Joos G, De-
rom E: Effects of pulmonary rehabilitation in 
patients with restrictive lung diseases. Chest 
2010; 137: 273–279. 
 44 Jastrzebski D, Gumola A, Gawlik R, Kozielski 
J: Dyspnea and quality of life in patients with 
pulmonary fibrosis after six weeks of respira-
tory rehabilitation. J Physiol Pharmacol 2006; 
 57(suppl 4):139–148. 
 45 Gloeckl R, Halle M, Kenn K: Interval versus 
continuous training in lung transplant candi-
dates: a randomized trial. J Heart Lung Trans-
plant 2012; 31: 934–941. 
 46 Gloeckl R, Halle M, Kenn K: Differences in 
feasibility of interval training between pa-
tients with end-stage COPD and interstitial 
lung disease before lung transplantation – a 
pilot study. Am J Respir Crit Care Med 2012; 
 185:A2390. 
 47 Gudmundsson G, Gislason T, Janson C, Lind-
berg E, Suppli Ulrik C, Brondum E, et al: De-
pression, anxiety and health status after hos-
pitalisation for COPD: a multicentre study in 
the Nordic countries. Respir Med 2006; 100: 
 87–93. 
 48 Stenzel N, Rief W, Kuhl K, Pinzer S, Kenn K: 
Fear of progression and end-of-life fear in 
COPD patients (in German). Pneumologie 
2012; 66: 111–118. 
 49 Sillen MJ, Speksnijder CM, Eterman RM, 
Janssen PP, Wagers SS, Wouters EF, et al: Ef-
fects of neuromuscular electrical stimulation 
of muscles of ambulation in patients with 
chronic heart failure or COPD: a systematic 
review of the English-language literature. 
Chest 2009; 136: 44–61. 
 50 Vivodtzev I, Debigare R, Gagnon P, Mainguy 
V, Saey D, Dube A, et al: Functional and mus-
cular effects of neuromuscular electrical stim-
ulation in patients with severe COPD: a ran-
domized clinical trial. Chest 2012; 141: 716–
725. 
 51 Gosselink R, De Vos J, van den Heuvel SP, 
Segers J, Decramer M, Kwakkel G: Impact of 
inspiratory muscle training in patients with 
COPD: what is the evidence? Eur Respir J 
2011; 37: 416–425. 
 52 Geddes EL, Reid WD, Crowe J, O’Brien K, 
Brooks D: Inspiratory muscle training in 
adults with chronic obstructive pulmonary 
disease: a systematic review. Respir Med 2005; 
 99: 1440–1458. 
 53 Gloeckl R, Heinzelmann I, Baeuerle S, Damm 
E, Schwedhelm AL, Diril M, et al: Effects of 
whole body vibration in patients with chronic 
obstructive pulmonary disease – a random-
ized controlled trial. Respir Med 2012; 106: 
 75–83. 
 54 Kohnlein T, Schonheit-Kenn U, Winterkamp 
S, Welte T, Kenn K: Noninvasive ventilation 
in pulmonary rehabilitation of COPD pa-
tients. Respir Med 2009; 103: 1329–1336. 
 55 Duiverman ML, Wempe JB, Bladder G, Jan-
sen DF, Kerstjens HA, Zijlstra JG, et al: Noc-
turnal non-invasive ventilation in addition to 
rehabilitation in hypercapnic patients with 
COPD. Thorax 2008; 63: 1052–1057. 
 56 Yan JH, Guo YZ, Yao HM, Pan L: Effects of 
tai chi in patients with chronic obstructive 
pulmonary disease: preliminary evidence. 
PLoS One 2013; 8:e61806. 
 57 Soni R, Munish K, Singh K, Singh S: Study of 
the effect of yoga training on diffusion capac-
ity in chronic obstructive pulmonary disease 
patients: a controlled trial. Int J Yoga 2012; 5: 
 123–127. 
 58 Leung RW, McKeough ZJ, Peters MJ, Alison 
JA: Short-form Sun-style t’ai chi as an exercise 
training modality in people with COPD. Eur 
Respir J 2013; 41: 1051–1057. 
 59 Collard HR, Loyd JE, King TE Jr, Lancaster 
LH: Current diagnosis and management of 
idiopathic pulmonary fibrosis: a survey of ac-
ademic physicians. Respir Med 2007; 101: 
 2011–2016. 
 60 Gloeckl R, Marinov B, Pitta F: Practical rec-
ommendations for exercise training in pa-
tients with COPD. Eur Respir Rev 2013; 
22:178–186.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:3
1:
31
 P
M
